<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Clinical and Imaging Follow-up Practices after Transarterial Therapy for Primary and Secondary Hepatic Malignancies" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/clinical-and-imaging-follow-up-practices-after-transarterial-therapy-for-primary-and-secondary-hepat/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/clinical-and-imaging-follow-up-practices-after-transarterial-therapy-for-primary-and-secondary-hepat/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2015-11-30T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Clinical and Imaging Follow-up Practices after Transarterial Therapy for Primary and Secondary Hepatic Malignancies" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T03:59:08+00:00","datePublished":"2015-11-30T17:00:00+00:00","description":"Rationale and Objectives","headline":"Clinical and Imaging Follow-up Practices after Transarterial Therapy for Primary and Secondary Hepatic Malignancies","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/clinical-and-imaging-follow-up-practices-after-transarterial-therapy-for-primary-and-secondary-hepat/"},"url":"https://clinicaltree.github.io/posts/clinical-and-imaging-follow-up-practices-after-transarterial-therapy-for-primary-and-secondary-hepat/"}</script><title>Clinical and Imaging Follow-up Practices after Transarterial Therapy for Primary and Secondary Hepatic Malignancies | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Clinical and Imaging Follow-up Practices after Transarterial Therapy for Primary and Secondary Hepatic Malignancies</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Clinical and Imaging Follow-up Practices after Transarterial Therapy for Primary and Secondary Hepatic Malignancies</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1448902800" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Nov 30, 2015 </em> </span> <span> Updated <em class="" data-ts="1681099148" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Ron C. Gaba MD</a> </em>, <em> <a href="">Mark O. Baerlocher MD</a> </em>, <em> <a href="">Boris Nikolic MD</a> </em>, <em> <a href="">Aradhana M. Venkatesan MD</a> </em>, <em> <a href="">Robert J. Lewowski MD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="1525 words"> <em>8 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>To characterize practices and quantify variation in longitudinal follow-up approaches among interventional radiologists (IRs) after liver transarterial locoregional therapy (LRT) in contemporary Interventional Oncology practice.</p><h2 id="materials-and-methods"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>In November/December 2014, Society of Interventional Radiology members were invited to participate in a survey regarding clinical and imaging follow-up of liver cancer patients treated with transarterial LRT. On survey closure, responses were compiled and analyzed.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The 30-item survey response rate was 11% (361 of 3290). Respondents were predominantly American IRs (311 of 355, 88%) who perform 1–5 LRTs monthly (196 of 354, 55%). Most (305 of 336, 91%) IRs reported longitudinal follow-up, with patient encounters within 1-month (73%, 211 of 290) postprocedure and every 3 months (68%, 196 of 287) thereafter and involvement in imaging (up to 80%, 235 of 290) ordering and evaluation. Preferred timing of first follow-up imaging (1 month vs. 3 months) and response criteria used (mRECIST favored) varied.</p><h2 id="conclusions"><span class="mr-2">Conclusions</span><a href="#conclusions" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Although IRs are actively involved in clinical and imaging follow-up of patients with liver malignancies treated with transarterial LRTs, there are differences in imaging frequency and response assessment. These data may serve as a starting point for standardization of LRT follow-up.</p><p>Longitudinal care of Interventional Oncology (IO) patients may have an important role for optimizing clinical outcomes and is critical for the acceptance of Interventional Radiologists (IRs) into the cancer care treatment paradigm. Although essential for patient and treatment response assessment, standardization of clinical and imaging follow-up protocols after transarterial locoregional therapy (LRT) of hepatic malignancies is hampered by a lack of supporting evidence in the IR literature to dictate suitable follow-up methods and limited guidance regarding posttreatment surveillance practices in current clinical practice guidelines . The development of standardized, evidence-based postprocedure surveillance practices after IO procedures is of paramount importance as these procedures have become integral to the care of the oncology patient. Although previous survey data have suggested variation in follow-up practices within the IR community , there remains a paucity of formally acquired information on the specific follow-up approaches used by IRs after IO therapies. This exploratory survey study thus aimed to characterize practices and quantify variation in follow-up approaches among IRs after liver transarterial LRTs in contemporary IO clinical practice to better understand currently used surveillance methods as a framework for future standardization of postprocedure care.</p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Between November 24 and December 29, 2014, 3290 American and international Physician members of the Society of Interventional Radiology (SIR) (In-Training, Scientist, and Clinical Associate members excluded) were requested to participate in a survey ( Appendix ) designed by the SIR IO Service Line and disseminated through an online survey company (SurveyMonkey, Palo Alto, CA). Invitations were sent via electronic mail from the SIR on survey commencement and 3 weeks after survey outset as a reminder for participation. The order of survey questions was identical for all respondents. Two variant but structurally and substantively analogous parallel survey pathways were used, with the final five survey questions (21–25 vs. 26–30) differing for participants based on the individual response to question 20. Responses to the password-protected questionnaire were anonymous, and no compensation was provided for participation. Survey settings were structured to allow only one response per invited e-mail address to prevent duplicate responses. On survey closure, responses were compiled and analyzed.</p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="respondent-demographics"><span class="mr-2">Respondent Demographics</span><a href="#respondent-demographics" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 1</p><p>Demographics of Survey Respondents and Practice Settings</p><p>Member Characteristics SIR Members (n = 361) ∗ Years in practice &lt;1 year 17 (5%) 1–5 years 92 (25%) 6–10 years 68 (19%) 11–15 years 56 (16%) &gt;15 years 127 (35%) Practice location United States 311 (88%) Canada 8 (2%) Europe 14 (4%) South America 5 (1%) Asia 17 (5%) Practice type Community-based hospital 185 (54%) University-based (academic) hospital 153 (44%) Free-standing facility 8 (2%) Practice size Individual 17 (5%) 2 IRs 32 (9%) 3–5 IRs 182 (51%) 6–10 IRs 86 (24%) &gt;10 IRs 41 (11%) Hospital size &lt;200 beds 31 (9%) 201–400 beds 114 (32%) 401–600 beds 97 (27%) 601–800 beds 54 (15%) 801–1000 beds 35 (10%) &gt;1000 beds 26 (7%) Liver transarterial therapies performed per month 1–5 196 (55%) 6–10 81 (23%) 11–15 31 (9%) &gt;15 46 (13%)</p><p>SIR, Society of Interventional Radiology; IR, interventional radiologist.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="transarterial-lrt-procedures"><span class="mr-2">Transarterial LRT Procedures</span><a href="#transarterial-lrt-procedures" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ClinicalandImagingFollowupPracticesafterTransarterialTherapyforPrimaryandSecondaryHepaticMalignancies/0_1s20S1076633215003414.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ClinicalandImagingFollowupPracticesafterTransarterialTherapyforPrimaryandSecondaryHepaticMalignancies/0_1s20S1076633215003414.jpg" alt="Figure 1, Preferred transarterial LRTs for different tumor types. HCC: c-TACE = 25%, DEB-TACE = 49%, bland particle embolization = 1%, 90 Y RE = 25%. mCRC: c-TACE = 9%, DEB-TACE = 28%, bland particle embolization = 1%, 90 Y RE = 62%. mNET: c-TACE = 16%, DEB-TACE = 19%, bland particle embolization = 22%, 90 Y RE = 43%. ICC: c-TACE = 14%, DEB-TACE = 28%, bland particle embolization = 7%, 90 Y RE = 51%. LRT, locoregional therapy; HCC, hepatocellular carcinoma; c-TACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; 90 Y RE, yttrium-90 radioembolization; mCRC, metastatic colorectal carcinoma; mNET, metastatic neuroendocrine tumor; ICC, intrahepatic cholangiocarcinoma." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="clinical-follow-up"><span class="mr-2">Clinical Follow-up</span><a href="#clinical-follow-up" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="frequency-and-duration"><span class="mr-2">Frequency and Duration</span><a href="#frequency-and-duration" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="laboratory-assessment"><span class="mr-2">Laboratory Assessment</span><a href="#laboratory-assessment" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="imaging-follow-up"><span class="mr-2">Imaging Follow-up</span><a href="#imaging-follow-up" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="follow-up-imaging-based-on-tumor-type-treated"><span class="mr-2">Follow-up Imaging Based on Tumor Type Treated</span><a href="#follow-up-imaging-based-on-tumor-type-treated" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 2</p><p>Preferred Imaging Follow-up Modality Based on Tumor Type Treated ∗ , †</p><p>Tumor Type CT MR Imaging PET-CT Ultrasound HCC 129/190 (68%) 144/190 (76%) 11/190 (6%) 1/190 (0.5%) mCRC 135/184 (73%) 71/184 (39%) 106/184 (58%) 2/184 (1%) mNET 140/183 (77%) 88/183 (48%) 34/183 (19%) 0/183 (0%) ICC 125/181 (69%) 119/181 (66%) 26/181 (14%) 0/181 (0%)</p><p>CT, computed tomography; MR, magnetic resonance; PET, positron emission tomography; HCC, hepatocellular carcinoma; mCRC, metastatic colorectal carcinoma; mNET, metastatic neuroendocrine tumor; ICC, intrahepatic cholangiocarcinoma.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ClinicalandImagingFollowupPracticesafterTransarterialTherapyforPrimaryandSecondaryHepaticMalignancies/1_1s20S1076633215003414.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ClinicalandImagingFollowupPracticesafterTransarterialTherapyforPrimaryandSecondaryHepaticMalignancies/1_1s20S1076633215003414.jpg" alt="Figure 2, Preferred response evaluation method for different tumor types. HCC: WHO = 2%, RECIST = 12%, mRECIST = 46%, EASL = 10%, no specific imaging response evaluation criteria = 27%. mCRC: c WHO = 3%, RECIST = 22%, mRECIST = 39%, EASL = 5%, no specific imaging response evaluation criteria = 28%. Other (e.g. mNET, ICC): WHO = 2%, RECIST = 18%, mRECIST = 36%, EASL = 4%, no specific imaging response evaluation criteria = 37%. HCC, hepatocellular carcinoma; WHO, World Health Organization; RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified Response Evaluation Criteria in Solid Tumors; EASL, European Association for the Study of the Liver; mCRC, metastatic colorectal carcinoma; mNET, metastatic neuroendocrine tumor; ICC, intrahepatic cholangiocarcinoma." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="follow-up-imaging-based-on-transarterial-lrt-used"><span class="mr-2">Follow-up Imaging Based on Transarterial LRT Used</span><a href="#follow-up-imaging-based-on-transarterial-lrt-used" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 3</p><p>Preferred Imaging Follow-up Modality Based on Transarterial LRT Used ∗ , †</p><p>Tumor Type CT MR Imaging PET-CT Ultrasound c-TACE 50/86 (58%) 44/86 (51%) 10/86 (12%) 2/86 (2%) DEB-TACE 48/83 (58%) 46/83 (55%) 12/83 (15%) 1/83 (1%) Bland embolization 46/79 (58%) 39/79 (49%) 8/79 (10%) 2/79 (3%) 90 Y RE 42/78 (54%) 38/78 (49%) 24/78 (31%) 0/78 (0%)</p><p>CT, computed tomography; MR, magnetic resonance; PET, positron emission tomography; c-TACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; 90 Y RE, yttrium-90 radioembolization.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ClinicalandImagingFollowupPracticesafterTransarterialTherapyforPrimaryandSecondaryHepaticMalignancies/2_1s20S1076633215003414.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ClinicalandImagingFollowupPracticesafterTransarterialTherapyforPrimaryandSecondaryHepaticMalignancies/2_1s20S1076633215003414.jpg" alt="Figure 3, Preferred response evaluation method for different LRTs. c-TACE: WHO = 0%, RECIST = 11%, mRECIST = 55%, EASL = 11%, no specific imaging response evaluation criteria = 23%. DEB-TACE: c WHO = 0%, RECIST = 9%, mRECIST = 56%, EASL = 11%, no specific imaging response evaluation criteria = 24%. Bland particle embolization: WHO = 0%, RECIST = 10%, mRECIST = 60%, EASL = 9%, no specific imaging response evaluation criteria = 21%. 90 Y RE: WHO = 0%, RECIST = 11%, mRECIST = 54%, EASL = 10%, no specific imaging response evaluation criteria = 26%. LRT, locoregional therapy; c-TACE, conventional transarterial chemoembolization; WHO, World Health Organization; RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified Response Evaluation Criteria in Solid Tumors; EASL, European Association for the Study of the Liver; DEB-TACE, drug-eluting bead transarterial chemoembolization; 90 Y RE, yttrium-90 radioembolization." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="acknowledgments"><span class="mr-2">Acknowledgments</span><a href="#acknowledgments" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="supplementary-data"><span class="mr-2">Supplementary data</span><a href="#supplementary-data" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Appendix</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Boas F.E., Do B., Louie J.D., et. al.: Optimal imaging surveillance schedules after liver-directed therapy for hepatocellular carcinoma. J Vasc Interv Radiol 2015; 26: pp. 69-73.</p><li><p>2. Bruix J., Sherman M., American Association for the Study of Liver D: Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: pp. 1020-1022.</p><li><p>3. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: pp. 908-943.</p><li><p>4. 2014. [cited 2015 August 13]; Available at: http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf</p><li><p>5. Gaba R.C.: Chemoembolization practice patterns and technical methods among interventional radiologists: results of an online survey. AJR Am J Roentgenol 2012; 198: pp. 692-699.</p><li><p>6. Brown D.B., Nikolic B., Covey A.M., et. al.: Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2012; 23: pp. 287-294.</p><li><p>7. Ibrahim S.M., Nikolaidis P., Miller F.H., et. al.: Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging 2009; 34: pp. 566-581.</p><li><p>8. Salem R., Lewandowski R.J., Kulik L., et. al.: Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: pp. 497-507. e492</p><li><p>9. Zivin S.P., Bui J.T., Knuttinen M.G., et. al.: Timing of imaging response after locoregional transarterial therapy (LRT): comparison between transarterial chemoembolization (TACE), and yttrium-90 radioembolization (Y-90 RE). J Vasc Interv Radiol 2015; 26: pp. S60.</p><li><p>10. Shim J.H., Lee H.C., Kim S.O., et. al.: Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012; 262: pp. 708-718.</p><li><p>11. Gillmore R., Stuart S., Kirkwood A., et. al.: EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011; 55: pp. 1309-1316.</p><li><p>12. Prajapati H.J., Spivey J.R., Hanish S.I., et. al.: mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol 2013; 24: pp. 965-973.</p><li><p>13. Salem R., Miller F.H., Yaghmai V., et. al.: Response assessment methodologies in hepatocellular carcinoma: complexities in the era of local and systemic treatments. J Hepatol 2013; 58: pp. 1260-1262.</p><li><p>14. Riaz A., Memon K., Miller F.H., et. al.: Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol 2011; 54: pp. 695-704.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-22/'>Volume 22</a>, <a href='/categories/issue-12/'>Issue 12</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Clinical%20and%20Imaging%20Follow-up%20Practices%20after%20Transarterial%20Therapy%20for%20Primary%20and%20Secondary%20Hepatic%20Malignancies%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fclinical-and-imaging-follow-up-practices-after-transarterial-therapy-for-primary-and-secondary-hepat%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Clinical%20and%20Imaging%20Follow-up%20Practices%20after%20Transarterial%20Therapy%20for%20Primary%20and%20Secondary%20Hepatic%20Malignancies%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fclinical-and-imaging-follow-up-practices-after-transarterial-therapy-for-primary-and-secondary-hepat%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fclinical-and-imaging-follow-up-practices-after-transarterial-therapy-for-primary-and-secondary-hepat%2F&text=Clinical%20and%20Imaging%20Follow-up%20Practices%20after%20Transarterial%20Therapy%20for%20Primary%20and%20Secondary%20Hepatic%20Malignancies%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/70-kvp-high-pitch-computed-tomography-pulmonary-angiography-with-40-ml-contrast-agent/"><div class="card-body"> <em class="small" data-ts="1448902800" data-df="ll" > Nov 30, 2015 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>70-kVp High-pitch Computed Tomography Pulmonary Angiography with 40 mL Contrast Agent</h3><div class="text-muted small"><p> Rationale and Objectives To assess image quality, radiation dose, and diagnostic accuracy of 70-kVp high-pitch computed tomography pulmonary angiography (CTPA) using 40 mL contrast agent and sinog...</p></div></div></a></div><div class="card"> <a href="/posts/a-survey-of-academic-radiology-department-chairs-on-hiring-recent-graduates-as-new-attending-physici/"><div class="card-body"> <em class="small" data-ts="1448902800" data-df="ll" > Nov 30, 2015 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>A Survey of Academic Radiology Department Chairs on Hiring Recent Graduates as New Attending Physicians</h3><div class="text-muted small"><p> Rationale and Objectives To determine hiring preferences among academic radiology department chairs with emphasis on recent residency and fellowship graduates. Materials and Methods With the ass...</p></div></div></a></div><div class="card"> <a href="/posts/association-between-confidence-level-of-acute-pulmonary-embolism-diagnosis-on-ctpa-images-and-clinic/"><div class="card-body"> <em class="small" data-ts="1448902800" data-df="ll" > Nov 30, 2015 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Association Between Confidence Level of Acute Pulmonary Embolism Diagnosis on CTPA images and Clinical Outcomes</h3><div class="text-muted small"><p> Rationale and Objectives The purpose was to evaluate clinical characteristics associated with low confidence in diagnosis of acute pulmonary embolism (PE) as expressed in computed tomography pulmo...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/association-between-confidence-level-of-acute-pulmonary-embolism-diagnosis-on-ctpa-images-and-clinic/" class="btn btn-outline-primary" prompt="Older"><p>Association Between Confidence Level of Acute Pulmonary Embolism Diagnosis on CTPA images and Clinical Outcomes</p></a> <a href="/posts/comparison-between-dual-energy-computed-tomography-and-ultrasound-in-the-diagnosis-of-gout-of-variou/" class="btn btn-outline-primary" prompt="Newer"><p>Comparison Between Dual-Energy Computed Tomography and Ultrasound in the Diagnosis of Gout of Various Joints</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
